David Hargreaves

AstraZeneca (Australia) — Australia

Materials Science · Physical Sciences

21h-index2.0kcitations78works5.92yr avg
OpenAlex↗ORCID↗Google Scholar↗Lab page↗

Accepting Students?

No reports yet. Know if this professor is taking students?

Research Topics

Enzyme Structure and Function(13), Monoclonal and Polyclonal Antibodies Research(12), Cell death mechanisms and regulation(8), Lung Cancer Treatments and Mutations(8), HER2/EGFR in Cancer Research(8)

Publications78 total

Optimization and Chemoproteomic Profiling of a Selective, Covalent Bfl-1-Targeting Cellular Tool
Journal of Medicinal Chemistry·2025
AZ14289671 is a highly selective and blood-brain barrier penetrant irreversible TKI that targets EGFRExon20 insertions
Cell Reports Medicine·2025Open Access
Highly Optimized CNS Penetrant Inhibitors of EGFR Exon20 Insertion Mutations
Journal of Medicinal Chemistry·2025· 5 cited
Structure-Based Discovery of a Series of Covalent, Orally Bioavailable, and Selective BFL1 Inhibitors
Journal of Medicinal Chemistry·2024· 3 cited
Optimization of Potent, Efficacious, Selective and Blood–Brain Barrier Penetrating Inhibitors Targeting EGFR Exon20 Insertion Mutations
Journal of Medicinal Chemistry·2024· 3 cited
Structure-Based Optimization of a Series of Covalent, Cell Active Bfl-1 Inhibitors
Journal of Medicinal Chemistry·2024· 7 citedOpen Access
Design of a Lead-Like Cysteine-Targeting Covalent Library and the Identification of Hits to Cys55 of Bfl-1
Journal of Medicinal Chemistry·2024· 10 citedOpen Access
Discovery and Optimization of Potent, Efficacious and Selective Inhibitors Targeting EGFR Exon20 Insertion Mutations
Journal of Medicinal Chemistry·2024· 8 citedOpen Access
Identification and Evaluation of Reversible Covalent Binders to Cys55 of Bfl-1 from a DNA-Encoded Chemical Library Screen
ACS Medicinal Chemistry Letters·2024· 17 citedOpen Access
Design of rigid protein–protein interaction inhibitors enables targeting of undruggable Mcl-1
Proceedings of the National Academy of Sciences·2023· 11 citedOpen Access
Not getting in too deep: A practical deep learning approach to routine crystallisation image classification
PLoS ONE·2023· 8 citedOpen Access
Not getting in too deep: a practical deep learning approach to routine crystallisation image classification
2022· 3 citedOpen Access
Virtual Screening in the Cloud Identifies Potent and Selective ROS1 Kinase Inhibitors
Journal of Chemical Information and Modeling·2022· 17 cited
Mechanistic insights into the rational design of masked antibodies
mAbs·2022· 11 citedOpen Access
Potent and Selective Inhibitors of the Epidermal Growth Factor Receptor to Overcome C797S-Mediated Resistance
Journal of Medicinal Chemistry·2021· 31 citedOpen Access
Studies Towards a Reversible EGFR C797S Triple Mutant Inhibitor Series
2020
Predicting the Effect of Chemical Factors on the pH of Crystallization Trials
iScience·2020· 7 citedOpen Access
Predicting the Effect of Chemical Factors on the pH of Crystallisation Trials
SSRN Electronic Journal·2020Open Access
Antibody fragments structurally enable a drug-discovery campaign on the cancer target Mcl-1
Acta Crystallographica Section D Structural Biology·2019· 13 citedOpen Access
Discovery and optimization of covalent Bcl-xL antagonists
Bioorganic & Medicinal Chemistry Letters·2019· 21 citedOpen Access
page 1 of 4Next →

Frequent Co-authors

Martin J. Packer(9), John B. Rafferty(8), Carine Guérot(8), Nancy Su(7), S. Gerhardt(7), Michelle L. Lamb(6), Philip B. Rawlins(6), William McCoull(6), Julie Wilson(6), Nicola Colclough(6), Nicolas Floc’h(6), Jonathan P. Orme(6), Richard A. Ward(6), Robert G. Lloyd(5), David W. Rice(5), Graeme R. Robb(5), Matthew A. Belmonte(4), Jeffrey W. Johannes(4), Jason G. Kettle(4), Alexander W. Hird(4)